Zinc-containing β-tricalcium phosphate (ZnTCP) nano particles were injected into zinc-deficient rats to promote osteogenesis. Sprague-Dawley (SD) rats (4 weeks old, average weight of 70 g) were divided into four groups: Normal rats (not ovariectomized (OVX)), Control rats (OVX), and OVX rats injected with a suspension of ZnTCP nano particles or ZnSO(4). The ZnTCP contained 6.17% zinc. The suspensions (0.6 mg as a zinc volume/0.2 ml) were injected around the jaw bone once a week for 12 weeks. Local effects on the bone mineral content (BMC) of jawbone, and systemic effects on body weight, the BMC of both femurs determined by X-ray computed tomography, and bone mechanical strength (BMS) measured by the three-point bending method, were examined. The BMC of jaw bone was significantly higher in the ZnTCP-treated group than un-treated or ZnSO(4)-treated group. Body weight, the BMC of femurs, and BMS were also significantly higher in the ZnTCP treated-group. The zinc-containing β-tricalcium phosphate nano particles were effective at preventing bone loss induced by ovariectomy in rats and have potential uses for treating periodontitis.
No takes yet. Share an insight, caveat, or question.
Tokudome et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: